SERA PROGNOSTICS, INC. - 10-K Filing Summary
Business Context and Reporting Period
Company: Sera Prognostics, Inc. (SERA)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Sera is a women's health company utilizing a proprietary proteomics and bioinformatics platform to develop blood-based biomarker tests. Its primary commercial product is the PreTRM test, a non-invasive blood test designed to predict the risk of spontaneous preterm birth. The company operates a CLIA-certified laboratory in Salt Lake City, Utah, and is classified as an Emerging Growth Company (EGC) and a Smaller Reporting Company.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $81 | $77 |
| Net Loss | $(31,928) | $(32,898) |
| Operating Expenses | $36,585 | $36,712 |
| Cash, Cash Equivalents, and Marketable Securities | $95,800 | $46,236 |
| Accumulated Deficit | $(311,722) | $(279,794) |
| Net Cash Used in Operating Activities | $(25,623) | $(14,189) |
Note: Revenue remains minimal as the company focuses on commercialization and evidence generation. The company reported a net loss per share of $(0.67) for 2025 compared to $(0.99) for 2024.
Material Changes vs. Prior Period
- Capital Raise: In February 2025, the company completed an underwritten public offering (the "February 2025 Offering"), raising approximately $53.6 million in net proceeds through the sale of Class A common stock and pre-funded warrants. This significantly increased cash reserves from ~$46 million in 2024 to ~$96 million in 2025.
- Operating Expenses: Total operating expenses decreased slightly by $127,000. Research and Development (R&D) expenses declined by $1.6 million, primarily due to the winding down of costs associated with the PRIME study following its conclusion. Conversely, Selling and Marketing expenses increased by $0.8 million due to strategic hiring of commercial personnel.
- Cost of Revenue: Increased by $82,000 (from $82k to $164k), reflecting higher costs associated with delivering test results despite minimal revenue recognition.
- Other Income: Increased by $0.8 million to $4.6 million, driven by higher interest income on marketable securities.
Guidance, Outlook, and Management Commentary
- Clinical Evidence Milestone: In January 2026, the company announced the publication of the PRIME study results in the Pregnancy Journal. Key findings included a 20% reduction in NICU admissions, a 20% reduction in neonatal morbidity/mortality, and a 56% reduction in babies born before 32 weeks. The study demonstrated that screening 4.2 patients saves one NICU day.
- Commercial Strategy: Management is shifting focus from a streamlined model to expanding commercial operations. In 2025, the company hired a Chief Commercial Officer and field sales representatives. The strategy involves targeting specific geographies with high preterm birth rates and leveraging the PRIME data to secure payer contracts.
- Liquidity and Runway: Management believes existing cash and cash equivalents are sufficient to fund operations through 2028. The company expects to continue incurring net losses as it invests in commercialization and pipeline development.
- Pipeline: Beyond PreTRM, the company is developing tests for preeclampsia, gestational diabetes, fetal growth restriction, and stillbirth, as well as a predictive analytics tool called "LikeMine."
- Risks: Key risks include the need for additional capital if commercialization is slower than expected, dependence on third-party payer reimbursement, and regulatory uncertainty regarding Laboratory Developed Tests (LDTs), although a recent court ruling vacated an FDA rule that would have imposed stricter regulations.
Investor Verification Checklist
- Reimbursement Status: Verify the current status of payer contracts and reimbursement rates for the PreTRM test, as revenue is heavily dependent on third-party payers.
- PRIME Study Impact: Assess the tangible commercial impact of the PRIME study publication on new payer agreements and test volume growth in 2026.
- Cash Burn Rate: Monitor the monthly cash burn rate to confirm the management's assertion of a runway extending through 2028.
- Regulatory Landscape: Track any new legislative or regulatory developments regarding LDTs that could impact the PreTRM test's market access.
- Pipeline Progress: Review updates on the development timeline for pipeline products (preeclampsia, gestational diabetes) to evaluate future revenue diversification.